Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review - Takeaways - MDSpire

Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review

  • By

  • Pacholczak-Madej, Renata

  • Łupkowski, Radosław

  • Górniak, Karolina

  • Puskulluoglu, Mirosława

  • June 26, 2026

  • 0 min

Share

  • 1

    Adult granulosa cell tumor (aGCT) is a rare ovarian malignancy with frequent late recurrences and limited treatment options.

  • 2

    Dysregulation of the cyclin D–CDK4/6–Rb axis is implicated in aGCT biology, indicating potential for targeted therapies.

  • 3

    Twenty-three reports were included in the scoping review, covering translational, preclinical, and clinical studies.

  • 4

    Preclinical studies indicated that CDK4/6 inhibition, especially with abemaciclib, reduced cell viability and tumor growth.

  • 5

    An ongoing phase II trial aims to systematically evaluate the therapeutic strategy of combining CDK4/6 inhibitors with endocrine therapy.

Original Source(s)

Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review

  • by Pacholczak-Madej, Renata , Łupkowski, Radosław , Górniak, Karolina , Puskulluoglu, Mirosława

  • June 26, 2026

Related Content

Prehabilitation in cancer care: an evolving field

Immune niche-associated and niche-regulated plasticity in glioblastoma: state transitions, immune escape, and therapeutic vulnerabilities

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study